Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease (CLARITY): statistical analysis plan for a randomised controlled Bayesian adaptive sample size trial

The CLARITY trial (Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY disease) is a two-arm, multi-centre, randomised controlled trial being run in India and Australia that investigates the effectiveness of angiotensin receptor blockers in addition to standard care compa...

Full description

Bibliographic Details
Main Authors: Bassi, A. (Author), Burrell, L.M (Author), CLARITY Trial Steering Committee (Author), Hockham, C. (Author), Jardine, M. (Author), Jha, V. (Author), Jones, M. (Author), Kotwal, S. (Author), McGree, J.M (Author), Pollock, C. (Author), Snelling, T. (Author), Wilcox, A. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
Adaptive sample size
Angiotensin receptor blockers
Bayesian design
Clinical trial
Coronavirus
Protocol
Statistical analysis plan
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items